Am. J. Respir. Cell Mol. Biol., Vol 11, No. 6, Dec 1994, 664-675.
Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline
NF Voelkel, RM Tuder, J Bridges and WP Arend
Department of Medicine, University of Colorado Health Sciences Center, Denver 80262.
Chronic pulmonary hypertension is associated with significant vascular
remodeling. We demonstrated recently in the monocrotaline (MCT) and chronic
hypoxia rat models of pulmonary hypertension that treatment with
platelet-activating factor (PAF) antagonists inhibited the development of
chronic pulmonary hypertension. PAF and other lipid mediators interact with
interleukin-1. We postulated that chronic treatment with a recombinant
human interleukin-1 receptor antagonist (IL-1ra) would inhibit development
of chronic pulmonary hypertension in animal models. Rats were either
injected with (60 mg/kg) MCT or exposed to a stimulated high altitude of
16,000 feet; half of the animals were treated with twice-daily injections
(2 mg/kg) of IL-1ra. At 3 wk after MCT injection or 3 wk of hypoxic
exposure, pulmonary artery pressure and right heart ventricle weight/(left
ventricle and septum weight), RV/(LV + S), were measured. IL-1ra treatment
reduced pulmonary hypertension and right heart hypertrophy in the MCT
model, but not in the chronic hypoxia model. Measurement of lung homogenate
IL-1 alpha by radioimmunoassay showed elevated levels in the MCT-treated
rats throughout the 3-wk observation period. IL-1ra treatment reduced the
levels of IL-1 alpha in lung tissue in most of the MCT-treated rats. MCT
treatment was also associated with an increase in lung mRNA for IL- 1
alpha, IL-1 beta, and IL-1ra. Immunohistology, using an antibody against
rat IL-1 alpha, revealed staining of alveolar structures and of vascular
and bronchial smooth muscle. In situ hybridization using a human IL-1 alpha
cDNA probe demonstrated increased expression of the IL- 1 alpha gene in the
lung cells after endotoxin or MCT treatment. Northern blot analysis
demonstrated low-level expression of IL-1 alpha mRNA in extracts of normal
rat lung and increased expression after endotoxin or MCT treatment. We
conclude that chronic treatment with human IL-1ra inhibited the development
of pulmonary hypertension in the inflammatory (MCT) model, but not in the
chronically hypoxic rats. This result indicates that IL-1 participates in
the pathogenesis of some forms of pulmonary hypertension.
This article has been cited by other articles:

|
 |

|
 |
 
H. Sawada, Y. Mitani, J. Maruyama, B. H. Jiang, Y. Ikeyama, F. A. Dida, H. Yamamoto, K. Imanaka-Yoshida, H. Shimpo, A. Mizoguchi, et al.
A Nuclear Factor-{kappa}B Inhibitor Pyrrolidine Dithiocarbamate Ameliorates Pulmonary Hypertension in Rats
Chest,
October 1, 2007;
132(4):
1265 - 1274.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Ito, T. Okada, H. Miyashita, T. Nomoto, M. Nonaka-Sarukawa, R. Uchibori, Y. Maeda, M. Urabe, H. Mizukami, A. Kume, et al.
Interleukin-10 Expression Mediated by an Adeno-Associated Virus Vector Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats
Circ. Res.,
September 28, 2007;
101(7):
734 - 741.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Taraseviciene-Stewart, R. Scerbavicius, K.-H. Choe, C. Cool, K. Wood, R. M. Tuder, N. Burns, M. Kasper, and N. F. Voelkel
Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension
Am J Physiol Lung Cell Mol Physiol,
October 1, 2006;
291(4):
L668 - L676.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Guignabert, B. Raffestin, R. Benferhat, W. Raoul, P. Zadigue, D. Rideau, M. Hamon, S. Adnot, and S. Eddahibi
Serotonin Transporter Inhibition Prevents and Reverses Monocrotaline-Induced Pulmonary Hypertension in Rats
Circulation,
May 31, 2005;
111(21):
2812 - 2819.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Lu, H. Shimpo, A. Shimamoto, A. J. Chong, C. R. Hampton, D. J. Spring, M. Yada, M. Takao, K. Onoda, I. Yada, et al.
Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats
J. Thorac. Cardiovasc. Surg.,
December 1, 2004;
128(6):
850 - 859.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Itoh, N. Nagaya, S. Murakami, T. Fujii, T. Iwase, H. Ishibashi-Ueda, C. Yutani, M. Yamagishi, H. Kimura, and K. Kangawa
C-type Natriuretic Peptide Ameliorates Monocrotaline-induced Pulmonary Hypertension in Rats
Am. J. Respir. Crit. Care Med.,
December 1, 2004;
170(11):
1204 - 1211.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. M. Tsai, M. Wang, M. Clauss, P. Sun, and D. R. Meldrum
Endothelial monocyte-activating polypeptide II causes NOS-dependent pulmonary artery vasodilation: a novel effect for a proinflammatory cytokine
Am J Physiol Regulatory Integrative Comp Physiol,
October 1, 2004;
287(4):
R767 - R771.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Jones, J. L. Walker, Y. Song, N. Weiss, W. V. Cardoso, R. M. Tuder, J. Loscalzo, and Y.-Y. Zhang
Effect of 5-lipoxygenase on the development of pulmonary hypertension in rats
Am J Physiol Heart Circ Physiol,
May 1, 2004;
286(5):
H1775 - H1784.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Deten, H. Millar, and H.-G. Zimmer
Catheterization of pulmonary artery in rats with an ultraminiature catheter pressure transducer
Am J Physiol Heart Circ Physiol,
November 1, 2003;
285(5):
H2212 - H2217.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Dorfmuller, F. Perros, K. Balabanian, and M. Humbert
Inflammation in pulmonary arterial hypertension
Eur. Respir. J.,
August 1, 2003;
22(2):
358 - 363.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Hoshikawa, P. Nana-Sinkam, M. D. Moore, S. Sotto-Santiago, T. Phang, R. L. Keith, K. G. Morris, T. Kondo, R. M. Tuder, N. F. Voelkel, et al.
Hypoxia induces different genes in the lungs of rats compared with mice
Physiol Genomics,
February 6, 2003;
12(3):
209 - 219.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Balabanian, A. Foussat, P. Dorfmuller, I. Durand-Gasselin, F. Capel, L. Bouchet-Delbos, A. Portier, A. Marfaing-Koka, R. Krzysiek, A.-C. Rimaniol, et al.
CX3C Chemokine Fractalkine in Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med.,
May 15, 2002;
165(10):
1419 - 1425.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. DORFMULLER, V. ZARKA, I. DURAND-GASSELIN, G. MONTI, K. BALABANIAN, G. GARCIA, F. CAPRON, A. COULOMB-LHERMINE, A. MARFAING-KOKA, G. SIMONNEAU, et al.
Chemokine RANTES in Severe Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med.,
February 15, 2002;
165(4):
534 - 539.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Suzuki, B. Murtuza, R. T. Smolenski, I. A. Sammut, N. Suzuki, Y. Kaneda, and M. H. Yacoub
Overexpression of Interleukin-1 Receptor Antagonist Provides Cardioprotection Against Ischemia-Reperfusion Injury Associated With Reduction in Apoptosis
Circulation,
September 18, 2001;
104(90001):
I-308 - 313.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Minamino, H. Christou, C.-M. Hsieh, Y. Liu, V. Dhawan, N. G. Abraham, M. A. Perrella, S. A. Mitsialis, and S. Kourembanas
Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia
PNAS,
July 5, 2001;
(2001)
161272598.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. TARASEVICIENE-STEWART, Y. KASAHARA, L. ALGER, P. HIRTH, G. MC MAHON, J. WALTENBERGER, N. F. VOELKEL, and R. M. TUDER
Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension
FASEB J,
February 1, 2001;
15(2):
427 - 438.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Stefanec
Endothelial Apoptosis: Could It Have a Role in the Pathogenesis and Treatment of Disease?
Chest,
March 1, 2000;
117(3):
841 - 854.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. TUDER, C. D. COOL, M. W. GERACI, J. WANG, S. H. ABMAN, L. WRIGHT, D. BADESCH, and N. F. VOELKEL
Prostacyclin Synthase Expression Is Decreased in Lungs from Patients with Severe Pulmonary Hypertension
Am. J. Respir. Crit. Care Med.,
June 1, 1999;
159(6):
1925 - 1932.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
C. Partovian, S. Adnot, S. Eddahibi, E. Teiger, M. Levame, P. Dreyfus, B. Raffestin, and C. Frelin
Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension
Am J Physiol Heart Circ Physiol,
December 1, 1998;
275(6):
H1948 - H1956.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Mitani, K. Maruyama, and M. Sakurai
Prolonged Administration of L-Arginine Ameliorates Chronic Pulmonary Hypertension and Pulmonary Vascular Remodeling in Rats
Circulation,
July 15, 1997;
96(2):
689 - 697.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
P. L. Jones and M. Rabinovitch
Tenascin-C Is Induced With Progressive Pulmonary Vascular Disease in Rats and Is Functionally Related to Increased Smooth Muscle Cell Proliferation
Circ. Res.,
December 1, 1996;
79(6):
1131 - 1142.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
T. Minamino, H. Christou, C.-M. Hsieh, Y. Liu, V. Dhawan, N. G. Abraham, M. A. Perrella, S. A. Mitsialis, and S. Kourembanas
Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia
PNAS,
July 17, 2001;
98(15):
8798 - 8803.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1994 American Thoracic Society.
|
|
|